- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
FDA Funds Initiative to Address Disparities in Real World Data
The FDA tapped the Reagan-Udall Foundation to launch the initiative.
The Reagan-Udall Foundation for the FDA (FDA Foundation) is launching the Real-world Accelerator to Improve the Standard of collection and curation of race and ethnicity data in health care (RAISE). The initiative, funded by the Food and Drug Administration’s Office of Minority Health and Health Equity (OMHHE), focuses on understanding, aligning, and disseminating best practices to improve real-world reporting, collection, curation, and integration of race and ethnicity data.
Efforts to improve race and ethnicity data collection and curation cross the domains of health disparities and health equity research, health care finance, health IT, workforce training, practice standards, and policy development. RAISE will convene a diverse group of leaders from across the health care ecosystem to collaborate on actionable solutions to improve the collection and curation of race and ethnicity data in health care settings, ultimately improving the quality of health care and medical products.
Continue reading this story here.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
